RT Journal Article SR Electronic T1 The contribution of common regulatory and protein-coding TYR variants in the genetic architecture of albinism JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.11.01.21265733 DO 10.1101/2021.11.01.21265733 A1 Michaud, Vincent A1 Lasseaux, Eulalie A1 Green, David J. A1 Gerrard, Dave T. A1 Plaisant, Claudio A1 , A1 Fitzgerald, Tomas A1 Birney, Ewan A1 Arveiler, Benoît A1 Black, Graeme C. A1 Sergouniotis, Panagiotis I. YR 2022 UL http://medrxiv.org/content/early/2022/03/28/2021.11.01.21265733.abstract AB Genetic diseases have been historically segregated into rare Mendelian and common complex conditions.1,2 Large-scale studies using genome sequencing are eroding this distinction and are gradually unmasking the underlying complexity of human traits.3–8 Aiming to gain insights into the genetic architecture of rare recessive disorders, we studied a cohort of 1,313 individuals with albinism, an archetypal Mendelian condition. We investigated the contribution of protein-coding and regulatory variants both rare and common. We focused on TYR, the gene encoding tyrosinase, and found that a high-frequency promoter variant, TYR c.-301C>T [rs4547091], modulates the penetrance of a prevalent, disease-associated missense change, TYR c.1205G>A [rs1126809]. We also found that homozygosity for a haplotype formed by three common, functionally-relevant variants, TYR c.[-301C;575C>A;1205G>A], is associated with a high probability of receiving an albinism diagnosis (OR>82). This genotype is also associated with reduced visual acuity and increased central retinal thickness in UK Biobank participants. Finally, we report how the combined analysis of rare and common variants increases diagnostic yield and informs genetic counselling in families with albinism.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWellcome Trust (200990/Z/16/Z, Transforming Genetic Medicine Initiative); Christopher Green; Retina UK and Fight for Sight (GR586, RP Genome Project - UK Inherited Retinal Disease Consortium); Health Education England; UK National Institute for Health Research (NIHR) Clinical Lecturer Programme (CL-2017-06-001); the French Albinism Association (Genespoir).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Comite de Protection des Personnes Sud-Ouest et Outre Mer III, Bordeaux, FranceI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. Phenotypic and genomic data from the Genomics England 100,000 Genomes Project and the UK Biobank project can be accessed by registered users with relevant approved applications; details on this can be found online at https://www.genomicsengland.co.uk/about-gecip/for-gecip-members/data-and-data-access and https://www.ukbiobank.ac.uk respectively.